论文部分内容阅读
目的观察黛力新(氟哌噻吨美利曲辛片)联合托特罗定治疗老年女性尿道综合征的临床疗效及安全性。方法 68例女性尿道综合征患者随机分为治疗组和对照组,各34例。治疗组给予托特罗定0.2 mg,2次/d;黛力新1片,1次/d。对照组仅给予托特罗定0.2 mg,2次/d。3个月为1个疗程。2~4周随访1次。治疗前后患者均行血尿粪常规、生化全套、B超检查。结果治疗3个月,治疗组和对照组总有效率分别为94.12%、70.59%,两组比较差异有统计学意义(χ2=6.48,P<0.05)。结论对临床单用托特罗定治疗老年女性尿道综合征疗效欠佳或伴有抑郁、焦虑状态的患者,加用黛力新治疗,可进一步提高疗效。
Objective To observe the clinical efficacy and safety of Deanxit (flupenthixol and melitracen tablets) combined with tolterodine in the treatment of urethral syndrome in elderly women. Methods 68 cases of female urethral syndrome were randomly divided into treatment group and control group, 34 cases each. The treatment group was given tolterodine 0.2 mg, 2 times / d, Deanxit 1, 1 / d. The control group was given tolterodine 0.2 mg twice daily. 3 months for a course of treatment. 2 to 4 weeks followed up 1 time. Before and after treatment of patients with routine urine and urine, biochemical full set, B-ultrasound. Results Three months after treatment, the total effective rates of the treatment group and the control group were 94.12% and 70.59%, respectively. There was significant difference between the two groups (χ2 = 6.48, P <0.05). Conclusion The clinical efficacy of tolterodine in the treatment of elderly women with urethral syndrome or poor efficacy or depression and anxiety in patients with dextromethorphan treatment can further improve the efficacy.